암에 중점을 둔 액체 생검 : 세계 시장

The global market for liquid biopsy with emphasis on cancer is expected to grow from $4.1 billion in 2026 and is projected to reach $8 billion by the end of 2031, at a compound annual growth rate (CAGR) of 14.1% during the forecast period of 2026 to 2031.

Report Scope

The report provides an overview of the global liquid biopsy with an emphasis on cancer market and analyzes market trends. It includes global revenue ($ million), using 2025 as the base year, estimated data for 2026, and projected data from 2026 through 2031.

The report segments the market by indication, technology, biomarker type, and application. By indication, the study includes lung cancer, breast cancer, colorectal cancer, prostate cancer, and other cancers. By technology, the market is segmented into next-generation sequencing (NGS), polymerase chain reaction (PCR), and other technologies. Based on biomarker type, the report covers circulating nucleic acids, circulating tumor cells (CTCs), exosomes, and circulating proteins. For application, the report includes therapy guidance, therapy monitoring, early cancer screening, and recurrence monitoring. Geographical regions covered in this study include North America (the U.S., Canada, and Mexico), Europe (Germany, the U.K., Italy, France, Spain, and the Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia-Pacific), the Middle East and Africa (MEA), and South America, with a focus on key countries in these regions.

The report focuses on the key driving trends and challenges shaping the market and vendor landscape. It analyzes and discusses emerging technologies related to the market.

The report concludes by analyzing the competitive landscape and highlighting the leading global liquid biopsy with an emphasis on cancer companies. It also includes a dedicated section on company profiles that covers overviews, key financials, product portfolios, and recent developments for major companies.

Report Includes

• 64 data tables and 58 additional tables
• An up-to-date review and analysis of the global market for liquid biopsy technologies
• Analyses of the global market trends, with sales data for 2023-2025, estimates for 2026, and projections of compound annual growth rates (CAGRs) through 2031
• Evaluation and forecast the overall market size for liquid biopsy technologies and their corresponding market share analysis by indication, technology, biomarker type, clinical application, and region
• Analysis of market opportunities with a review of Porter's Five Forces model and industry supply chain analysis, considering both micro- and macro environmental factors prevailing in the market
• Explanation of market drivers, restraints and other forces impacting the global market
• Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, regulatory framework and reimbursement scenarios, and ESG trends of the market
• Identification of companies best positioned to meet this demand due to their proprietary technologies, mergers and acquisitions, joint ventures and other strategic alliances
• Descriptive profiles of the leading global companies, including Guardant Health, Natera Inc., Exact Sciences Corp., Illumina Inc., and F. Hoffmann-La Roche Ltd.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Overview
• Current Market Scenario
• Segmental Analysis
• Regional Analysis
• Technological Advances
• Conclusion

Chapter 2 Market Overview

• Overview
• Liquid Biopsy Versus Traditional Biopsy
• Porter's Five Forces Analysis in the Liquid Biopsy with Emphasis on the Cancer Market
• Potential for New Entrants (Low to Moderate)
• Bargaining Power of Suppliers (Moderate to High)
• Bargaining Power of Buyers (Moderate)
• Threat of Substitutes (Moderate to High)
• Competition in the Industry (High)
• Macroeconomic Factor Analysis
• Cancer Funding
• Reimbursement Policy
• The U.S. Tariff Scenario

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Rising Incidence of Cancer
• Growing Awareness of Early Cancer Detection
• Advantages of Liquid Biopsy Over Conventional Tissue Biopsy
• Market Restraints
• Lower Sensitivity of Certain Liquid Biopsy Procedures
• Market Opportunities
• Rising Significance of Precision Medicine
• Growing Oncology Diagnostics Demand in Emerging Markets

Chapter 4 Regulatory Landscape

• U.S.
• Europe
• Other Regions

Chapter 5 Emerging Technologies and Developments

• Emerging Technologies
• Microfluidics-Based Devices
• Nanotechnology
• Artificial Intelligence
• Clinical Trials Analysis
• Key Takeaways
• Clinical Trials Analysis, by Type of Study
• Clinical Trials Analysis, by Status
• Clinical Trials Analysis, by Phase
• Patent Analysis
• Key Takeaways
• Patents, by Year
• By Top Applicant
• By Top Owner
• By Jurisdiction

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Market Analysis by Indication
• Key Takeaways
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Other Cancers
• Market Analysis by Technology
• Key Takeaways
• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Other Technologies
• Market Analysis by Biomarker Type
• Key Takeaways
• Circulating Nucleic Acids
• Circulating Tumor Cells (CTCs)
• Exosomes
• Circulating Protein
• Market Analysis by Application
• Key Takeaways
• Therapy Monitoring
• Recurrence Monitoring
• Early Cancer Screening
• Therapy Guidance
• Geographic Breakdown
• Market Analysis by Region
• Key Takeaways
• North America
• Europe
• Asia-Pacific
• South America
• Middle East and Africa (MEA)

Chapter 7 Competitive Intelligence

• Key Takeaways
• Competitive Landscape
• Leading Companies in the Liquid Biopsy with Emphasis on Cancer Market
• Guardant Health
• Natera
• Exact Science Corp.
• Key Developments and Strategies

Chapter 8 Appendix

• Methodology
• Sources
• Abbreviations
• Company Profiles
• BIO-RAD LABORATORIES INC.
• BIO-TECHNE
• DXCOVER LTD
• EXACT SCIENCES CORP.
• F. HOFFMANN-LA ROCHE LTD.
• FREEENOME HOLDINGS INC.
• GUARDANT HEALTH INC.
• ILLUMINA INC.
• MYRIAD GENETICS INC.
• NATERA INC.
• NEOGENOMICS LABORATORIES
• NOVIGENIX AI
• PERSONALIS INC.
• QIAGEN
• THERMO FISHER SCIENTIFIC INC.
• List of a Few Emerging Start-ups/ Market Disruptors